Online citations, reference lists, and bibliographies.

Phase I Study Of An Immunomodulatory Thalidomide Analog, CC-4047, In Relapsed Or Refractory Multiple Myeloma.

S. Schey, P. Fields, J. Bartlett, I. A. Clarke, G. Ashan, R. Knight, M. Streetly, A. Dalgleish
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
PURPOSE To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma. PATIENTS AND METHODS Twenty-four relapsed or refractory patients were treated with a dose-escalating regimen of oral CC-4047. Clinical responses and adverse effects were identified, and peripheral T-cell subsets, serum cytokines, and proangiogenic factors were evaluated. RESULTS CC-4047 was tolerated with no serious nonhematologic adverse events. All patients were eligible for analysis. Toxicity criteria during the initial 4 weeks of study were used to define the maximum-tolerated dose (MTD). During this period, one patient withdrew with a deep vein thrombosis (DVT) probably caused by an undiagnosed primary melanoma with lymphadenopathy in the groin, one patient withdrew because of progressive disease (PD), and three patients discontinued with neutropenia. Nineteen of 24 patients continued on treatment beyond 4 weeks to PD or development of a serious adverse event. Three further patients developed a DVT at 4, 9, and 11 months. Treatment resulted in a greater than 25% reduction in paraprotein in 67% of patients, 13 patients (54%) experienced a greater than 50% reduction in paraprotein, and four (17%) of 24 patients entered complete remission. The MTD was 2 mg/d. All patients showed increased CD45RO expression on CD4(+) and CD8(+) cells, with a concomitant decrease in CD45RA(+) cells. CC-4047 treatment was associated with significantly increased serum interleukin (IL)-2 receptor and IL-12 levels, which is consistent with activation of T cells and monocytes and macrophages. CONCLUSION This study demonstrates the safety and efficacy of CC-4047. The MTD of CC-4047 orally was 2 mg/d. This is the first report demonstrating in vivo T-cell costimulation by this class of compound, supporting a potential role for CC-4047 as an immunostimulatory adjuvant treatment.
This paper references
Thalidomide and immunomodulatory drugs as cancer therapy.
N. Raje (2002)
Thalidomide in the Management of Multiple Myeloma
S. Schey (2002)
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
K. Dredge (2002)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications
T. Hideshima (2001)
Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.
A. Nakajima (1998)
Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.
N. Giuliani (2003)
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
K. Neben (2001)
Immunotherapeutic and antitumour potential of thalidomide analogues
J. Marriott (2001)
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.
A. Osterborg (1998)
Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset
P. A. Haslett (1998)
Antitumor activity of thalidomide in refractory multiple myeloma.
S. Singhal (1999)
Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.
T. Rasmussen (2003)
Thalidomide and its analogues have distinct and opposing effects on TNF‐α and TNFR2 during co‐stimulation of both CD4+ and CD8+ T cells
J. Marriott (2002)
An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment.
S. Schey (2003)
Thromboembolic events during treatment with thalidomide.
E. Urbauer (2002)
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
M. Zangari (2003)
Thalidomide is an inhibitor of angiogenesis.
R. D'Amato (1994)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
P. Richardson (2002)
Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies.
Q. Yi (1995)
Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.
H. Geitz (1996)
Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.
J. Gollob (1998)
A phase 2 study of bortezomib in relapsed, refractory myeloma.
P. Richardson (2003)
Antitumor and antimetastatic activity of interleukin 12 against murine tumors
M. Brunda (1993)
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
A. Moreira (1993)
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen‐ and antigen‐stimulated human peripheral blood mononuclear cell cultures
S. M. McHugh (1995)
Thalidomide analogs as emerging anti-cancer drugs
K. Dredge (2003)
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
L. Corral (1999)
Myeloma: new insights
S. Schey (2003)
Thalidomide in the management of multiple myeloma.
B. Barlogie (2001)
Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.
C. Coughlin (1998)
Deregulated cytokine network and defective Th1 immune response in multiple myeloma
M. Frassanito (2001)
Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity1
K. Dredge (2002)

This paper is referenced by
Management of Treatment Complications and Supportive Care
Francis K Buadi (2010)
Novel therapies in monoclonal gammopathies
Rubén Niesvizky (2012)
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
N. Daver (2013)
Множественная миелома (лечение рецидивов и рефрактерных форм): обзор литературы и собственные данные. Часть III
Stanislav S. Bessmeltsev (2014)
Inhibitors of NF-κB derived from thalidomide
E. J. C. de-Blanco (2007)
Cardiotoxicity of Non-Cardiovascular Drugs
G. Minotti (2010)
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
J. Infante (2011)
How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions
M. Offidani (2011)
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
S. Usmani (2014)
Impact of pomalidomide therapy in multiple myeloma: a recent survey
A. Kumar (2014)
Thalidomide and lenalidomide: Mechanism-based potential drug combinations
S. Vallet (2008)
The molecular mechanism of thalidomide analogs in hematologic malignancies
Stefanie Lindner (2016)
Absorption, metabolism and excretion of ( 14 C)pomalidomide in humans following oral administration
Matthew HoffmannClaudia (2013)
The safety of pomalidomide for the treatment of multiple myeloma
J. Jones (2016)
Single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
H. E. Eve (2012)
The changing treatment paradigm in patients with newly diagnosed multiple myeloma: implications for nursing.
J. Tariman (2005)
Angiogenesis in multiple myeloma: Implications in myeloma therapy
S. Martin (2004)
Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells
E. D. Bruyne (2007)
Immunomodulatory agents in oncology
T. Zimmerman (2009)
Bone marrow microenvironment and the identification of new targets for myeloma therapy
K. Podar (2009)
Immune modulatory agents in hematopoietic malignancies.
Irina S Idler (2011)
Cap-Dependent Protein Translation Initiation in Multiple Myeloma: An Attractive Target for Therapy
Shirong Li (2013)
Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma
A. Petrov (2017)
Thalidomide and Its Analogs as Anticancer Agents
Y. Huang (2008)
Thalidomide in multiple myeloma.
T. Moehler (2006)
Immunotherapeutic approaches to treat multiple myeloma
M. W. Roeven (2014)
Phase1/‐2 study of Pomalidomide in myelofibrosis
R. Mesa (2010)
Cost–effectiveness of lenalidomide in multiple myeloma
Steve A. Schey (2010)
Current challenges in the management of patients with relapsed/refractory multiple myeloma.
Jesús F. San Miguel (2011)
Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
K. Matsue (2015)
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
A. Dispenzieri (2012)
signaling and platelet function 3 β IIb α integrin The tetraspanin superfamily member CD 151 regulates outside-in
D. E. Jackson (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar